733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.

BACKGROUND: Cytomegalovirus (CMV) disease is associated with increased morbidity and mortality following solid organ and hematopoietic cell transplantation. Currently, standard of care CMV treatments often have significant myelosuppressive or renal toxicities. Given letermovir’s favorable safety pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Bocco, Isabel H, Cheng, Matthew, Aleissa, Muneerah M, Arbona, Esther I, Chen, Kaiwen, Zhou, Eric, Beluch, Katherine, Cho, Alyssa, Burchett, Sandra, Hammond, Sarah P, Issa, Nicolas C, Sherman, Amy C, Marty, Francisco M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752064/
http://dx.doi.org/10.1093/ofid/ofac492.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752064/
http://dx.doi.org/10.1093/ofid/ofac492.024

Ejemplares similares